Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005654 | 0.80 | CALM1 (0.37) | CALM1CAMKK2ALDH1A1 | |
| SCHEMBL13005691 | 0.79 | OPRM1 (0.43) | CALM1CAMKK2 | |
| SCHEMBL13005432 | 0.78 | OPRM1 (0.44) | CALM1CAMKK2ALDH1A1 | |
| SCHEMBL13005625 | 0.76 | BCHE (0.47) | CALM1CAMKK2SLC6A4 | |
| SCHEMBL13005558 | 0.75 | KDM4E (0.54) | CALM1CAMKK2 | |
| SCHEMBL13005440 | 0.74 | CALM1 (0.59) | CALM1CAMKK2ALDH1A1HTR2ASLC6A4 | |
| SCHEMBL13005422 | 0.73 | CALM1 (0.48) | CALM1CAMKK2ALDH1A1 | |
| SCHEMBL13005681 | 0.73 | CALM1 (0.48) | CALM1CAMKK2ALDH1A1MEP1B | |
| SCHEMBL13005684 | 0.71 | TAAR1 (0.53) | CALM1CAMKK2OPRL1ALDH1A1 | |
| SCHEMBL13005692 | 0.71 | TSHR (0.54) | CALM1CAMKK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |